Tuesday June 2nd 2026 | 10.00am - 5.00pm

*** This session is not open to everyone. It is an invitation only event ***

Sponsored by:

Mithrl logo

Pivot from Proof of Concept to Proven ROI 

AI has moved beyond experimentation. Across biopharma, the question is no longer if AI can deliver value but where and how is value being delivered, how to deploy it at scale and embed it into core business and R&D workflows.  

The PharmAI Leaders Exchange brings together 25 senior decision makers for delivering measurable returns from AI investments. Through candid, closed-door discussions, participants will share practical lessons on moving beyond pilots and proof-of-concept initiatives toward enterprise deployment, robust governance, and sustained performance. 

PharmAI roundtable

Moderators

What to expect

Participants will leave with actionable perspectives on how to accelerate deployment, strengthen data foundations, align teams around measurable KPIs, and ultimately realize the full return on their AI investments.

Sessions will be moderated by senior industry leaders for open dialogue on successes, failures, and next steps.

Who should attend

This Exchange is designed exclusively for senior decision-makers responsible for setting strategy, allocating  resources and driving implementation.

Attendance is limited to Pharma leaders at Director level and above. 

Event format

The Leaders Exchange is structured around five interactive roundtables, each designed to enable peer-to-peer discussion and practical knowledge sharing in a small group setting.

This meeting will be conducted in a trusted environment using the Chatham House Rule. Participants can use the information received, but neither the identity nor the affiliation of the speakers can be revealed.  

What the conversation will focus on 

10.00 Opening Remarks

Ice Breaker Exercise and Introductions

10.30 Strategic AI Investment: From Proof to Impact 

  • Are we moving beyond proof-of-concept and delivering measurable ROI, leading to increased executive buy-in and scaled adoption of AI in drug discovery? 

  • Managing expectations: AI won't shrink timelines from 10 years to 2, but it can optimize decision-making, derisk assets, and improve pipeline productivity. How do we separate hype from actionable opportunity? 

  • How to build and manage an AI investment portfolio across the R&D pipeline—from early discovery to clinical validation—to ensure value at every stage. 

Moderator: Rohit Arora, Associate Director, External Innovation Strategic Assessment - Data Science & Digital Health, Johnson & Johnson

11.30 Quantifying AI Success: KPIs That Matter 

  • How do we define and align AI-related KPIs with core business goals: Is success measured by user adoption, model performance, or validated clinical impact? 

  • Where is the real value of AI in drug discovery and how do we track it? 

  • Avoiding vanity metrics by shifting focus to meaningful outcomes like reduced failure rates, faster decision-making, and enhanced pipeline productivity. 

Moderator: Emily Rose Holzinger, Senior Director of Statistical Genetics, Bristol Myers Squibb 

12.30 Networking Lunch 

1.30 Unlocking Innovation Through Pre-Competitive & Startup Collaborations 

  • Pre-competitive partnerships as a mechanism for risk-sharing, learning, and algorithm enhancement without compromising IP. 

  • How to effectively collaborate with startups. What makes partnerships succeed or fail? How to create win-win feedback loops? 

  • Building shared benchmarks, synthetic datasets, or testbeds that accelerate algorithm validation across the ecosystem. 

Moderator: Sudeshna Fisch, Senior Distinguished Scientist, Sanofi 

2.30 Training AI: Data, Metadata, and Strategic Feedback Loops 

  • Building AI-ready data products: Addressing fragmented, incomplete, or noisy datasets through better metadata, annotation and standardization. 

  • Creating robust feedback loops between AI developers and users to enhance algorithm performance and contextual relevance. 

  • How to prioritize datasets across therapeutic areas to align with high-value AI use cases (e.g., target identification, patient stratification). 

Moderator: Madhu Sevvana, Principal Scientist, Structural Biology and Protein Design (LMR), Sanofi

3.30 Building Future-Ready AI Teams in Pharma 

  • As AI becomes core to R&D strategy, how are pharma org charts evolving? What new roles, hybrid skills, and inter-team collaborations are emerging? 

  • How to effectively hire and develop professionals who understand biology, statistics, and AI and how to scale their impact quickly. 

  • Upskilling within pharma constraints: What’s working, what isn’t, and lessons from the field. 

  • Centralized AI teams vs. embedded domain experts: How do you strike the right balance for innovation and operational efficiency? 

  • What critical skill sets will define success in AI-enhanced drug development over the next 5–10 years? 

Moderator: Vishal Thapar, Director, Product Manager, Applied AI Biomarker Development, AstraZeneca 

4.30 Closing remarks 

  • Everyone to summarise what three things they’ve learned or want to take home to implement at their company. 

** Please note that the names, job titles and company names of confirmed attendees will be shared with prospective participants and attendees at the PharmAI Leaders Exchange. If you would prefer not to have your name, job title and company name shared, please let me know when you confirm your attendance.